Loading...

Lotus Bio-Technology Development

OTCPK:LBTD
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LBTD
OTCPK
$273K
Market Cap
  1. Home
  2. US
  3. Media
Company description

Lotus Bio-Technology Development Corp., a bio-technology development company, focuses on refining organic materials, and production of natural consumer related products in China. The last earnings update was 583 days ago. More info.


Add to Portfolio Compare Print
  • Lotus Bio-Technology Development has significant price volatility in the past 3 months.
LBTD Share Price and Events
7 Day Returns
3.1%
OTCPK:LBTD
2.2%
US Entertainment
0.8%
US Market
1 Year Returns
-66.3%
OTCPK:LBTD
11.3%
US Entertainment
5.9%
US Market
LBTD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lotus Bio-Technology Development (LBTD) 3.1% 120% 65% -66.3% - -89%
US Entertainment 2.2% 3.5% 9.2% 11.3% 68% 96.4%
US Market 0.8% 2.6% 10.6% 5.9% 37.7% 45.5%
1 Year Return vs Industry and Market
  • LBTD underperformed the Entertainment industry which returned 11.3% over the past year.
  • LBTD underperformed the Market in United States of America which returned 5.9% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Lotus Bio-Technology Development undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Lotus Bio-Technology Development is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lotus Bio-Technology Development has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Lotus Bio-Technology Development. This is due to cash flow or dividend data being unavailable. The share price is $0.0033.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lotus Bio-Technology Development's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lotus Bio-Technology Development's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:LBTD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2016-12-31) in USD Not available
OTCPK:LBTD Share Price ** OTCPK (2019-04-18) in USD $0
United States of America Entertainment Industry PE Ratio Median Figure of 23 Publicly-Listed Entertainment Companies 22.78x
United States of America Market PE Ratio Median Figure of 3,078 Publicly-Listed Companies 18.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lotus Bio-Technology Development.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Lotus Bio-Technology Development, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Lotus Bio-Technology Development's expected growth come at a high price?
Raw Data
OTCPK:LBTD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Entertainment Industry PEG Ratio Median Figure of 19 Publicly-Listed Entertainment Companies 2.6x
United States of America Market PEG Ratio Median Figure of 2,108 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lotus Bio-Technology Development, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lotus Bio-Technology Development's assets?
Raw Data
OTCPK:LBTD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2016-12-31) in USD Not available
OTCPK:LBTD Share Price * OTCPK (2019-04-18) in USD $0
United States of America Entertainment Industry PB Ratio Median Figure of 55 Publicly-Listed Entertainment Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,172 Publicly-Listed Companies 1.93x

* Primary Listing of Lotus Bio-Technology Development.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Take a look at our analysis of LBTD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Entertainment industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Lotus Bio-Technology Development's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Entertainment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Entertainment industry average (and greater than 0)? (1 check)
  5. Lotus Bio-Technology Development has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Lotus Bio-Technology Development expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lotus Bio-Technology Development has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected Entertainment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lotus Bio-Technology Development expected to grow at an attractive rate?
  • Unable to compare Lotus Bio-Technology Development's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Lotus Bio-Technology Development's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Lotus Bio-Technology Development's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:LBTD Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Entertainment Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
United States of America Entertainment Industry Revenue Growth Rate Market Cap Weighted Average 11.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:LBTD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:LBTD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2016-12-31 0 -1
2016-09-30 0 -1
2016-06-30 0 -1
2016-03-31 0 -1
2015-12-31 0 0
2015-09-30 0 0
2015-06-30 0 0
2015-03-31 0 0
2014-12-31 0 0
2014-09-30 0 0
2014-06-30 0 0
2014-03-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Lotus Bio-Technology Development is high growth as no earnings estimate data is available.
  • Unable to determine if Lotus Bio-Technology Development is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:LBTD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Lotus Bio-Technology Development Company Filings, last reported 2 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:LBTD Past Financials Data
Date (Data in USD Millions) EPS *
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 0.00
2016-03-31 0.00
2015-12-31 0.00
2015-09-30 0.00
2015-06-30 0.00
2015-03-31 0.00
2014-12-31 0.00
2014-09-30 0.00
2014-06-30 0.00
2014-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lotus Bio-Technology Development will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of LBTD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Lotus Bio-Technology Development's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Media companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Lotus Bio-Technology Development's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Lotus Bio-Technology Development's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lotus Bio-Technology Development has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Lotus Bio-Technology Development performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Lotus Bio-Technology Development has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • Lotus Bio-Technology Development's last earnings update was 583 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lotus Bio-Technology Development's growth in the last year to its industry (Entertainment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Lotus Bio-Technology Development's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Lotus Bio-Technology Development's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Lotus Bio-Technology Development's 1-year growth to the US Entertainment industry average as past earnings data has not been reported.
Earnings and Revenue History
Lotus Bio-Technology Development's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lotus Bio-Technology Development Company Filings, last reported 2 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:LBTD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2016-12-31 -0.79 0.79
2016-09-30 -0.78 0.77
2016-06-30 -0.78 0.78
2016-03-31 -0.78 0.78
2015-12-31 0.01 -0.01
2015-09-30 0.01 -0.01
2015-06-30 0.01 -0.01
2015-03-31 -0.02 0.02
2014-12-31 -0.07 0.07
2014-09-30 -0.07 0.06
2014-06-30 -0.07 0.06
2014-03-31 -0.04 0.04
2013-12-31 -0.04 0.01
2013-09-30 -0.06 0.04
2013-06-30 -0.06 0.04
2013-03-31 -0.06 0.04
2012-12-31 -0.07 0.05
2012-09-30 -0.04 0.02
2012-06-30 -0.04 0.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Lotus Bio-Technology Development has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Lotus Bio-Technology Development has efficiently used its assets last year compared to the US Entertainment industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Lotus Bio-Technology Development improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Lotus Bio-Technology Development's management and board experience and expertise to assess their ability to deliver on their strategic promises.
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Lotus Bio-Technology Development's filings and announcements here.
  3. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Lotus Bio-Technology Development's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Entertainment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lotus Bio-Technology Development has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Lotus Bio-Technology Development's financial health and their level of debt?

In this section we usually analyse Lotus Bio-Technology Development's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Lotus Bio-Technology Development has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lotus Bio-Technology Development's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Lotus Bio-Technology Development has not reported sufficient balance sheet data.
  • Unable to establish if Lotus Bio-Technology Development's long term commitments exceed its cash and other short term assets as Lotus Bio-Technology Development has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Lotus Bio-Technology Development's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Lotus Bio-Technology Development has a high level of physical assets or inventory without balance sheet data.
  • Unable to verify if debt is covered by short term assets as Lotus Bio-Technology Development has not reported sufficient balance sheet data.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lotus Bio-Technology Development Company Filings, last reported 2 years ago.

OTCPK:LBTD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2016-12-31 -0.08 0.00 0.00
2016-09-30 -0.07 0.06 0.00
2016-06-30 -0.06 0.05 0.00
2016-03-31 -0.06 0.00 0.00
2015-12-31 -0.06 0.05 0.00
2015-09-30 -0.05 0.05 0.00
2015-06-30 -0.05 0.04 0.00
2015-03-31 -0.05 0.00 0.00
2014-12-31 -0.10 0.06 0.00
2014-09-30 -0.08 0.06 0.00
2014-06-30 -0.08 0.00 0.00
2014-03-31 -0.05 0.03 0.00
2013-12-31 -0.02 0.00 0.00
2013-09-30 -0.02 0.00 0.00
2013-06-30 -0.01 0.00 0.00
2013-03-31 -0.01 0.01 0.00
2012-12-31 0.01 0.00 0.02
2012-09-30 -0.01 0.02 0.01
2012-06-30 -0.02 0.04 0.03
  • Unable to establish if Lotus Bio-Technology Development's level of debt is high without past debt data.
  • Unable to establish if Lotus Bio-Technology Development's debt level has increased without past 5-year debt data.
  • Unable to verify if debt is well covered by operating cash flow as Lotus Bio-Technology Development has not reported sufficient balance sheet data.
  • Unable to confirm if the interest payments on Lotus Bio-Technology Development's debt are well covered by earnings due to lack of past financial data.

Next steps:

  1. Take a look at our analysis of LBTD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  3. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Lotus Bio-Technology Development's financial data was last updated here.
  4. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  5. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Lotus Bio-Technology Development's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lotus Bio-Technology Development has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Lotus Bio-Technology Development's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lotus Bio-Technology Development dividends.
If you bought $2,000 of Lotus Bio-Technology Development shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lotus Bio-Technology Development's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lotus Bio-Technology Development's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:LBTD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Entertainment Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lotus Bio-Technology Development has not reported any payouts.
  • Unable to verify if Lotus Bio-Technology Development's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lotus Bio-Technology Development's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lotus Bio-Technology Development has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lotus Bio-Technology Development's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lotus Bio-Technology Development afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lotus Bio-Technology Development has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Lotus Bio-Technology Development's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zoltan Nagy
COMPENSATION $0
AGE 52
TENURE AS CEO 2.2 years
CEO Bio

Mr. Zoltan Nagy has been Chief Executive Officer, President, Chief Financial Officer and Director of Lotus Bio-Technology Development Corp. since April 10, 2019, He has been the Principal Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Treasurer and Secretary of Black Rock Petroleum Company since April 24, 2013. Mr. Nagy served as the Chief Executive Officer, President and Director at Lotus Bio-Technology Development Corp. from February 10, 2017 to June 19, 2017. Mr. Nagy served as the Principal Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Secretary and Treasurer of Starflick.com Incorporated since March 24, 2011 until April 1, 2016 and served as its Compliance Officer. Mr. Nagy serves as the President of Branded Beverages, Inc. He served as the Chief Executive Officer, Treasurer and Secretary of Raptor Technology Group Inc. from August 30, 2007 to April 27, 2011 and served as its Chief Financial Officer and Principal Accounting Officer until April 27, 2011. He served as the President of Raptor Technology Group Inc. from December 20, 2010 to April 27, 2011 and also again as the President from August 30, 2007 to November 30, 2010. Since 2002, Mr. Nagy has been active in the filmed entertainment industry as an Actor, Production Assistant, Camera Operator and Director on several television shows, commercials and motion pictures. He has been a Director at Black Rock Petroleum Company since April 24, 2013 and Giddy-Up Productions Inc. since August 2007. He served as a Director of Raptor Technology Group Inc. He served as a Director of Starflick.com Incorporated since March 24, 2011 until April 1, 2016. Mr. Nagy received a Diploma in film direction from Los Angeles City College in 1993.

CEO Compensation
  • Insufficient data for Zoltan to compare compensation growth.
  • Insufficient data for Zoltan to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Zoltan Nagy

TITLE
CEO, President
AGE
52
TENURE
2.2 yrs
Board of Directors

Zoltan Nagy

TITLE
CEO, President
AGE
52
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Lotus Bio-Technology Development's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lotus Bio-Technology Development has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Lotus Bio-Technology Development Corp., a bio-technology development company, focuses on refining organic materials, and production of natural consumer related products in China. The company was formerly known as Starflick.com and changed its name to Lotus Bio-Technology Development Corp. in April 2016. Lotus Bio-Technology Development Corp. was founded in 2011 and is based in Cave Creek, Arizona.

Details
Name: Lotus Bio-Technology Development Corp.
LBTD
Exchange: OTCPK
Founded: 2011
$273,159
82,775,500
Website: http://
Address: Lotus Bio-Technology Development Corp.
28202 North 58th Street,
Cave Creek,
Arizona, 85331,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK LBTD Common Shares Pink Sheets LLC US USD 15. Mar 2013
Number of employees
Current staff
Staff numbers
0
Lotus Bio-Technology Development employees.
Industry
Movies and Entertainment
Media
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 00:37
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2017/09/13
Last earnings reported: 2016/12/31
Last annual earnings reported: 2016/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.